市場調査レポート
商品コード
1377959
ダニコパン新薬の考察と市場予測 - 2032年Danicopan Emerging Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
ダニコパン新薬の考察と市場予測 - 2032年 |
出版日: 2023年11月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 1~3営業日
|
当レポートでは、ダニコパン新薬の主要7市場(米国、ドイツ、フランス、イタリア、スペイン、英国、日本)について調査分析し、作用機序、用法と用量、研究開発活動の考察、市場予測などを提供しています。
“"Danicopan Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about danicopan for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets. A detailed picture of the danicopan for PNH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the danicopan for PNH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the danicopan market forecast analysis for PNH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PNH.
ALXN2040 (also known as danicopan) is an investigational, first-in-class, oral proximal factor D inhibitor developed by Achillion, a wholly owned subsidiary of Alexion. Factor D (FD), a serine protease, catalyzes the cleavage of complement factor B into Ba and Bb, which allows for the formation of the AP C3 convertase. By inhibiting FD, danicopan, blocks C3 convertase formation, the control point for AP activation, and the amplification of all pathways. This leads to the inhibition of C3 cleavage, C3 fragment deposition, terminal pathway activation, and MAC formation.
The drug has already received Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) by the FDA and PRIME designation and ODD by the EMA. Phase III development is currently being initiated for danicopan as an add-on therapy for PNH patients with extravascular hemolysis (EVH). Besides, the company is conducting Phase II studies to determine the effectiveness of ACH-0144471 in patients with PNH who have an inadequate response to eculizumab monotherapy.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Danicopan Analytical Perspective by DelveInsight
This report provides a detailed market assessment of danicopan for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of danicopan for PNH covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions